Does This Metric Tell Investors All They Need to Know About Gilead Sciences?

Does This Metric Tell Investors All They Need to Know About Gilead Sciences?
Does This Metric Tell Investors All They Need to Know About Gilead Sciences?
Jason Hawthorne, The Motley Fool

The company has stagnated since its revolutionary HIV and hepatitis C drugs were released, and one metric shows why investors should look elsewhere for returns.